Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:02
05/14/20
05/14
09:02
05/14/20
09:02
INO

Inovio

$13.35 /

+0.45 (+3.49%)

, ALLO

Allogene Therapeutics

$30.99 /

-1.56 (-4.79%)

, IMUX

Immunic

$10.00 /

-0.72 (-6.72%)

, WIX

Wix.com

$166.19 /

+0.22 (+0.13%)

, ETRN

Equitrans Midstream

$6.93 /

-0.44 (-5.97%)

, EQM

EQT Midstream Partners

$16.86 /

-0.99 (-5.55%)

, XCUR

Exicure

$2.47 /

-0.2 (-7.49%)

, NCLH

Norwegian Cruise Line

$10.29 /

-0.79 (-7.13%)

, SSYS

Stratasys

$16.34 /

-0.22 (-1.33%)

, CSCO

Cisco

$41.91 /

-1.28 (-2.96%)

, SDC

SmileDirectClub

$7.70 /

-0.39 (-4.82%)

, I

Intelsat

$0.79 /

-0.175 (-18.23%)

, MGNX

MacroGenics

$26.50 /

-0.86 (-3.14%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
XCUR Exicure
$2.47 /

-0.2 (-7.49%)

WIX Wix.com
$166.19 /

+0.22 (+0.13%)

SSYS Stratasys
$16.34 /

-0.22 (-1.33%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

MGNX MacroGenics
$26.50 /

-0.86 (-3.14%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

I Intelsat
$0.79 /

-0.175 (-18.23%)

ETRN Equitrans Midstream
$6.93 /

-0.44 (-5.97%)

EQM EQT Midstream Partners
$16.86 /

-0.99 (-5.55%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

05/14/20 Oppenheimer
Allogene Therapeutics price target raised to $50 from $44 at Oppenheimer
05/14/20 Jefferies
Jefferies raises price target on 'ASCO winner' Allogene Therapeutics to $45
05/14/20 SunTrust
Allogene Therapeutics downgraded to Hold from Buy at SunTrust
05/14/20 Stifel
Durability remains a key question for Allogene's ALLO-501, says Stifel
IMUX Immunic
$10.00 /

-0.72 (-6.72%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
WIX Wix.com
$166.19 /

+0.22 (+0.13%)

04/13/20 SunTrust
Wix's offering, business model will remain 'relatively durable,' says SunTrust
04/13/20 William Blair
Wix.com shareholder letter 'better than feared,' says William Blair
03/19/20 Wedbush
Wix.com price target lowered to $105 from $165 at Wedbush
03/17/20 Rosenblatt
Wix.com upgraded to Neutral from Sell at Rosenblatt
ETRN Equitrans Midstream
$6.93 /

-0.44 (-5.97%)

04/27/20 Wells Fargo
Equitrans Midstream double upgraded to Overweight at Wells Fargo
04/27/20 Wells Fargo
Equitrans Midstream upgraded to Overweight from Underweight at Wells Fargo
01/07/20 Wells Fargo
Equitrans Midstream downgraded to Underweight at Wells Fargo
01/07/20 Wells Fargo
Equitrans Midstream downgraded to Underweight from Equal Weight at Wells Fargo
EQM EQT Midstream Partners
$16.86 /

-0.99 (-5.55%)

04/27/20 Wells Fargo
EQT Midstream Partners double upgraded to Overweight at Wells Fargo
04/27/20 Wells Fargo
EQT Midstream Partners upgraded to Overweight from Underweight at Wells Fargo
01/07/20 Wells Fargo
EQT Midstream Partners downgraded to Underweight at Wells Fargo
01/07/20 Wells Fargo
EQT Midstream Partners downgraded to Underweight from Equal Weight at Wells Fargo
XCUR Exicure
$2.47 /

-0.2 (-7.49%)

12/24/19 H.C. Wainwright
Exicure financing reflects growing institutional demand, says H.C. Wainwright
12/11/19 H.C. Wainwright
H.C. Wainwright reiterates Buy on Exicure after 'favorable' clinical data
11/20/19 Guggenheim
Guggenheim starts Exicure with Buy rating, $9 price target
11/20/19 Guggenheim
Exicure initiated with a Buy at Guggenheim
NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

05/13/20 Wells Fargo
Wells Fargo downgrades Norwegian Cruise Line on 'elongated' industry recovery
05/13/20 Wells Fargo
Norwegian Cruise Line downgraded to Equal Weight from Overweight at Wells Fargo
05/05/20 Goldman Sachs
Goldman says capital raise gives Norwegian runway to endure slow recovery
04/23/20 Stifel
Stifel calls Royal best positioned cruise operator, ups target to $48
SSYS Stratasys
$16.34 /

-0.22 (-1.33%)

04/27/20 Piper Sandler
Stratasys Q1 results likely to be below plan, says Piper Sandler
04/06/20 JPMorgan
Stratasys, 3D Systems losing share amid new entrants, says JPMorgan
03/24/20 Piper Sandler
Stratasys price target lowered to $20 from $24 at Piper Sandler
02/27/20 Loop Capital
Loop Capital backs Sell on 3D Systems given macro, coronavirus headwinds
CSCO Cisco
$41.91 /

-1.28 (-2.96%)

05/14/20 Morgan Stanley
Cisco too broadly exposed to macro to be more positive, says Morgan Stanley
05/14/20 Baird
Cisco price target raised to $48 from $46 at Baird
05/14/20 MKM Partners
Cisco price target raised to $48 from $40 at MKM Partners
05/14/20 Wells Fargo
Cisco price target raised to $55 from $50 at Wells Fargo
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

05/14/20 BofA
BofA double downgrades SmileDirectClub to Underperform on recovery worries
05/14/20 BofA
SmileDirectClub downgraded to Underperform from Buy at BofA
04/07/20 Goldman Sachs
SmileDirectClub downgraded to Sell from Neutral at Goldman Sachs
04/06/20 Guggenheim
SmileDirectClub removed from Best Ideas list at Guggenheim
I Intelsat
$0.79 /

-0.175 (-18.23%)

04/01/20 Goldman Sachs
Intelsat downgraded to Sell from Neutral at Goldman Sachs
03/27/20 Cowen
Intelsat downgraded to Market Perform at Cowen
03/27/20 Cowen
Intelsat downgraded to Market Perform from Outperform at Cowen
02/10/20 Raymond James
Intelsat risk/reward more fairly valued, says Raymond James
MGNX MacroGenics
$26.50 /

-0.86 (-3.14%)

05/12/20 Credit Suisse
MacroGenics price target raised to $30 from $13 at Credit Suisse
05/06/20 H.C. Wainwright
MacroGenics price target raised to $22 from $18 at H.C. Wainwright
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
MacroGenics initiated with an Underweight at Barclays
XCUR Exicure
$2.47 /

-0.2 (-7.49%)

WIX Wix.com
$166.19 /

+0.22 (+0.13%)

SSYS Stratasys
$16.34 /

-0.22 (-1.33%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

MGNX MacroGenics
$26.50 /

-0.86 (-3.14%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

I Intelsat
$0.79 /

-0.175 (-18.23%)

ETRN Equitrans Midstream
$6.93 /

-0.44 (-5.97%)

EQM EQT Midstream Partners
$16.86 /

-0.99 (-5.55%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

I Intelsat
$0.79 /

-0.175 (-18.23%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

XCUR Exicure
$2.47 /

-0.2 (-7.49%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

MGNX MacroGenics
$26.50 /

-0.86 (-3.14%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

I Intelsat
$0.79 /

-0.175 (-18.23%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

WIX Wix.com
$166.19 /

+0.22 (+0.13%)

SSYS Stratasys
$16.34 /

-0.22 (-1.33%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

NCLH Norwegian Cruise Line
$10.29 /

-0.79 (-7.13%)

INO Inovio
$13.35 /

+0.45 (+3.49%)

I Intelsat
$0.79 /

-0.175 (-18.23%)

ETRN Equitrans Midstream
$6.93 /

-0.44 (-5.97%)

EQM EQT Midstream Partners
$16.86 /

-0.99 (-5.55%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

On The Fly
Fly Intel: After-Hours Movers » 19:04
05/13/20
05/13
19:04
05/13/20
19:04
KNSA

Kiniksa

$18.97 /

-2.13 (-10.09%)

, ARVN

Arvinas

$51.00 /

-4.4 (-7.94%)

, SDC

SmileDirectClub

$7.70 /

-0.39 (-4.82%)

, JACK

Jack in the Box

$63.59 /

-2.29 (-3.48%)

, VRTU

Virtusa

$31.75 /

-1.95 (-5.79%)

, ONEM

1Life Healthcare

$26.78 /

-0.44 (-1.62%)

, PANL

Pangaea Logistics

$2.30 /

-0.03 (-1.29%)

, FCAU

Fiat Chrysler

$7.90 /

-0.27 (-3.30%)

, MA

MasterCard

$269.58 /

-2.66 (-0.98%)

, IMGN

ImmunoGen

$4.09 /

-0.19 (-4.44%)

, ALLO

Allogene Therapeutics

$30.99 /

-1.56 (-4.79%)

, IMUX

Immunic

$10.00 /

-0.72 (-6.72%)

, OII

Oceaneering

$4.64 /

-0.26 (-5.31%)

, FLO

Flowers Foods

$22.64 /

+0.17 (+0.76%)

, CSCO

Cisco

$41.91 /

-1.28 (-2.96%)

, RVLV

Revolve Group

$14.92 /

+0.49 (+3.40%)

, BRP

BRP Group

$8.99 /

-1.01 (-10.10%)

, JAKK

JAKKS Pacific

$0.59 /

-0.0939 (-13.81%)

, RKDA

Arcadia Biosciences

$4.88 /

+0.15 (+3.17%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

05/13/20 Piper Sandler
Arvinas pullback represents a buying opportunity, says Piper Sandler
05/13/20 Wedbush
Arvinas removed from Best Ideas List at Wedbush
05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Oppenheimer
Arvinas initiated with a Perform at Oppenheimer
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

04/07/20 Goldman Sachs
SmileDirectClub downgraded to Sell from Neutral at Goldman Sachs
04/06/20 Guggenheim
SmileDirectClub removed from Best Ideas list at Guggenheim
03/02/20
Fly Intel: Top five analyst downgrades
03/02/20 UBS
SmileDirectClub downgraded to Neutral from Buy at UBS
JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

05/11/20 SunTrust
Jack in the Box price target raised to $79 from $66 at SunTrust
04/16/20 SunTrust
Jack in the Box price target raised to $66 from $49 at SunTrust
04/16/20 Wells Fargo
Jack in the Box price target lowered to $72 from $105 at Wells Fargo
04/16/20 Oppenheimer
Jack in the Box price target lowered to $70 from $96 at Oppenheimer
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

02/07/20 Needham
Virtusa price target raised to $56 from $48 at Needham
01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
01/06/20 Wedbush
Wedbush says buy Virtusa on weakness as market 'overreacts' to Citi renewal
01/06/20 Wedbush
Virtusa pullback on Citi renewal news a buying opportunity, says Wedbush
ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

02/25/20 Morgan Stanley
1Life Healthcare initiated with an Overweight at Morgan Stanley
02/25/20 JPMorgan
1Life Healthcare initiated with an Overweight at JPMorgan
02/25/20 SunTrust
1Life Healthcare initiated with a Buy at SunTrust
02/25/20 Citi
1Life Healthcare initiated with a Neutral at Citi
PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
MA MasterCard
$269.58 /

-2.66 (-0.98%)

05/06/20 Stephens
Visa franchises will exit recession stronger, says Stephens
05/06/20 Stephens
MasterCard price target raised to $304 from $286 at Stephens
05/04/20 BMO Capital
Visa price target lowered to $213 from $234 at BMO Capital
04/30/20 RBC Capital
MasterCard price target raised to $308 from $287 at RBC Capital
IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

05/13/20 H.C. Wainwright
Allogene's TurboCARs shows promise for solid tumors, says H.C. Wainwright
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
IMUX Immunic
$10.00 /

-0.72 (-6.72%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
OII Oceaneering
$4.64 /

-0.26 (-5.31%)

04/24/20 Citi
Oceaneering upgraded to Buy from Neutral at Citi
04/05/20 Bernstein
Oceaneering upgraded to Market Perform from Underperform at Bernstein
03/19/20 Wolfe Research
Oceaneering downgraded to Peer Perform from Outperform at Wolfe Research
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices
FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
CSCO Cisco
$41.91 /

-1.28 (-2.96%)

04/17/20 KeyBanc
Cisco downgraded to Sector Weight from Overweight at KeyBanc
04/16/20 Cleveland Research
Cisco dips after Cleveland Research calls out partners' worsening trends
04/14/20 MKM Partners
Cisco price target lowered to $40 from $48 at MKM Partners
04/06/20 Raymond James
Cisco price target lowered to $48 from $54 at Raymond James
RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

03/19/20
Fly Intel: Top five analyst downgrades
03/19/20 Jefferies
Jefferies cuts Revolve Group to Hold, lowers price target to $9
03/19/20 Jefferies
Revolve Group downgraded to Hold from Buy at Jefferies
03/18/20 Nomura Instinet
Revolve Group initiated with a Neutral at Nomura Instinet
BRP BRP Group
$8.99 /

-1.01 (-10.10%)

03/26/20 Keefe Bruyette
BRP Group price target lowered to $16 from $22 at Keefe Bruyette
02/21/20 Northcoast
BRP Group downgraded to Neutral from Buy at Northcoast
11/18/19
Fly Intel: Top five analyst initiations
11/18/19 Jefferies
BRP Group initiated with a Hold at Jefferies
JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

12/13/19 Jefferies
Removal, delay of China tariffs give 'reprieve' to toy companies, says Jefferies
RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

06/06/19 H.C. Wainwright
Arcadia Biosciences price target lowered to $14 from $20 at H.C. Wainwright
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

  • 14
    May
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

Hot Stocks
Immunic up 45% afterhours following ph.2 trial of IMU-838 approval in Germany  16:30
05/13/20
05/13
16:30
05/13/20
16:30
IMUX

Immunic

$10.02 /

-0.7 (-6.53%)

 
ShowHide Related Items >><<
IMUX Immunic
$10.02 /

-0.7 (-6.53%)

IMUX Immunic
$10.02 /

-0.7 (-6.53%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
IMUX Immunic
$10.02 /

-0.7 (-6.53%)

IMUX Immunic
$10.02 /

-0.7 (-6.53%)

Hot Stocks
Immunic's Phase 2 trial in COVID-19 approved in Germany » 16:06
05/13/20
05/13
16:06
05/13/20
16:06
IMUX

Immunic

$10.02 /

-0.7 (-6.53%)

Immunic has received…

Immunic has received first regulatory approval from Germany's BfArM - Bundesinstitut fur Arzneimittel und Medizinprodukte - to initiate a phase 2 clinical trial of its selective oral DHODH inhibitor, IMU-838, in coronavirus disease 2019. The CALVID-1 study is a prospective, phase 2 clinical trial in approximately 230 patients with moderate COVID-19, designed to evaluate efficacy, safety and tolerability of IMU-838. Dosing of the first patient is expected to occur later this month. Top-line data is expected to be available later this year. IMU-838 had successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 - SARS-CoV-2 -. Specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19. IMU-838 has already been tested in about 650 individuals. The aim of the CALVID-1 trial is to investigate IMU-838 as an oral treatment option for COVID-19 and to enable the use of IMU-838 as a treatment for current and potential future pandemic threats. Inclusion criteria are hospitalized adult patients with a confirmed SARS-CoV-2 infection fulfilling clinical status category 3 or 4. The primary endpoint will be the proportion of patients free of invasive ventilation throughout the entire study period. Secondary endpoints include duration of hospitalization, duration of intensive care unit treatment, 28-day all-cause mortality, time to clinical improvement and viral titer reduction. If clinical activity of IMU-838 is confirmed by the Independent Data Monitoring Committee, an expansion of this trial into a confirmatory phase 3 trial could be recommended.

ShowHide Related Items >><<
IMUX Immunic
$10.02 /

-0.7 (-6.53%)

IMUX Immunic
$10.02 /

-0.7 (-6.53%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
IMUX Immunic
$10.02 /

-0.7 (-6.53%)

IMUX Immunic
$10.02 /

-0.7 (-6.53%)

Initiation
Fly Intel: Top five analyst initiations » 10:10
05/11/20
05/11
10:10
05/11/20
10:10
EIX

Edison International

$55.62 /

-1.3 (-2.28%)

, BAND

Bandwidth

$111.00 /

+3.1 (+2.87%)

, IMUX

Immunic

$9.85 /

+1.2 (+13.87%)

, FRPT

Freshpet

$72.78 /

-0.72 (-0.98%)

, ABBV

AbbVie

$84.69 /

+0.63 (+0.75%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Edison International (EIX) initiated with an Overweight at KeyBanc. 2. Bandwidth (BAND) initiated with an Outperform at William Blair. 3. Immunic (IMUX) initiated with a Buy, $45 price target at H.C. Wainwright. 4. Freshpet (FRPT) initiated with a Neutral at Citi. 5. AbbVie (ABBV) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
EIX Edison International
$55.62 /

-1.3 (-2.28%)

05/11/20 KeyBanc
Edison International initiated with an Overweight, $66 target at KeyBanc
05/11/20 KeyBanc
Edison International initiated with an Overweight at KeyBanc
05/04/20 BofA
Edison International upgraded to Buy on easing capital raise concerns at BofA
05/04/20 BofA
Edison International upgraded to Buy from Neutral at BofA
BAND Bandwidth
$111.00 /

+3.1 (+2.87%)

05/11/20 William Blair
Bandwidth initiated with an Outperform at William Blair
05/11/20 William Blair
Bandwidth initiated with an Outperform at William Blair
05/01/20 Needham
Bandwidth price target raised to $96 from $85 at Needham
03/26/20 Baird
Bandwidth added as a Fresh Pick at Baird
IMUX Immunic
$9.85 /

+1.2 (+13.87%)

05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
FRPT Freshpet
$72.78 /

-0.72 (-0.98%)

05/11/20 Citi
Freshpet initiated with a Neutral at Citi
05/05/20 SunTrust
Freshpet price target raised to $60 from $55 at SunTrust
04/21/20 BofA
Freshpet initiated with a Neutral at BofA
02/26/20 SunTrust
Freshpet price target raised to $70 from $45 at SunTrust
ABBV AbbVie
$84.69 /

+0.63 (+0.75%)

05/11/20 Morgan Stanley
AbbVie resumed with an Overweight at Morgan Stanley
05/01/20 Piper Sandler
Piper Sandler remains a buyer of 'resilient' AbbVie after earnings
04/21/20 SunTrust
Allergan downgraded to Hold from Buy at SunTrust
04/20/20
Fly Intel: Top five analyst upgrades
Initiation
Immunic initiated with a Buy, $45 price target at H.C. Wainwright » 07:25
05/11/20
05/11
07:25
05/11/20
07:25
IMUX

Immunic

$8.65 /

+0.25 (+2.98%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Immunic with a Buy rating and $45 price target. Immunic is an emerging biotech company with a lead asset, IMU-838, in Phase 2 testing across three autoimmune indications: relapsing-remitting multiple sclerosis, inflammatory bowel disease and primary sclerosing cholangitis, Selvaraju tells investors in a research note. The analyst views IMU-838 as a "substantially de-risked asset," noting it is based on a predecessor molecule, vidofludimus, which previously went through extensive clinical testing and was dosed in over 300 human subjects. Superior safety and tolerability of IMU-838 should permit it to gain traction in other autoimmune and inflammatory conditions as well, contends Selvaraju, who sees "substantial near-term value-driving catalysts."

ShowHide Related Items >><<
IMUX Immunic
$8.65 /

+0.25 (+2.98%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Chardan
Immunic initiated with a Buy at Chardan
Hot Stocks
Immunic down 2.5% after reporting Q1 results  06:46
05/08/20
05/08
06:46
05/08/20
06:46
IMUX

Immunic

$8.40 /

-0.15 (-1.75%)

 
ShowHide Related Items >><<
IMUX Immunic
$8.40 /

-0.15 (-1.75%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Chardan
Immunic initiated with a Buy at Chardan
Earnings
Immunic reports Q1 EPS (79c), consensus (95c) » 06:45
05/08/20
05/08
06:45
05/08/20
06:45
IMUX

Immunic

$8.40 /

-0.15 (-1.75%)

"The global…

"The global coronavirus disease 2019 (COVID-19) pandemic has led to a period of intense, additional focus for Immunic, as we quickly recognized the potential of our lead asset, selective oral DHODH inhibitor, IMU-838, as a possible therapeutic for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, given its already well-recognized, broad-spectrum antiviral effects," stated Daniel Vitt, Ph.D., CEO and President of Immunic. "After performing preclinical testing, we recently announced that, in cellular assays, IMU-838 successfully demonstrated antiviral activity against SARS-CoV-2 at blood concentrations which are well below those associated with IMU-838 dosing regimens studied in our ongoing and previous clinical trials. Based on these positive results, we are preparing a phase 2 clinical development program for IMU-838 as a potential treatment for this devastating disease." Dr. Vitt continued, "On the heels of this encouraging preclinical data, we were able to bolster our financial position with a successful $15.0 million financing. As a result, we expect to be well funded through key, near-term milestones including top-line data from both our phase 2 trial of IMU-838 for relapsing-remitting multiple sclerosis, or RRMS, expected in the third quarter of this year, as well as results from the investigator-sponsored phase 2 trial for IMU-838 in primary sclerosing cholangitis, or PSC, expected in early 2021."

ShowHide Related Items >><<
IMUX Immunic
$8.40 /

-0.15 (-1.75%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Chardan
Immunic initiated with a Buy at Chardan
Over a month ago
On The Fly
Fly Intel: Pre-market Movers » 08:58
04/22/20
04/22
08:58
04/22/20
08:58
IMUX

Immunic

$7.83 /

-1.27 (-13.96%)

, MNK

Mallinckrodt

$3.05 /

-0.41 (-11.85%)

, EXPE

Expedia

$57.37 /

-2.55 (-4.26%)

, T

AT&T

$29.83 /

-1.15 (-3.71%)

, DAL

Delta Air Lines

$23.05 /

-0.61 (-2.58%)

, KMB

Kimberly-Clark

$139.61 /

-0.21 (-0.15%)

, DGX

Quest Diagnostics

$94.57 /

-0.55 (-0.58%)

, TER

Teradyne

$60.88 /

-1.58 (-2.53%)

, CMG

Chipotle

$781.00 /

-29.69 (-3.66%)

, BIIB

Biogen

$329.79 /

-9.33 (-2.75%)

, NFLX

Netflix

$434.01 /

-3.65 (-0.83%)

, IBKR

Interactive Brokers

$43.27 /

-1.09 (-2.46%)

, IRBT

iRobot

$50.98 /

+0.41 (+0.81%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
IMUX Immunic
$7.83 /

-1.27 (-13.96%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Chardan
Immunic initiated with a Buy at Chardan
MNK Mallinckrodt
$3.05 /

-0.41 (-11.85%)

02/25/20 Stifel
Mallinckrodt clearing path for shares to be revalued, says Stifel
01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
09/10/19 Stifel
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
09/09/19 Stifel
Mallinckrodt price target lowered to $8 from $20 at Stifel
EXPE Expedia
$57.37 /

-2.55 (-4.26%)

04/01/20
Fly Intel: Top five analyst downgrades
04/01/20 Argus
Expedia downgraded to Hold from Buy at Argus
04/01/20 Argus
Expedia downgraded to Hold from Buy at Argus
03/31/20 RBC Capital
Expedia price target lowered to $79 from $100 at RBC Capital
T AT&T
$29.83 /

-1.15 (-3.71%)

04/17/20 Benchmark
Netflix initiated with a Sell at Benchmark
04/14/20 SunTrust
Roku price target lowered to $110 from $160 at SunTrust
04/09/20 Guggenheim
AT&T price target trimmed to $39 after financial update at Guggenheim
DAL Delta Air Lines
$23.05 /

-0.61 (-2.58%)

04/21/20 Deutsche Bank
Delta Air Lines price target lowered to $47 from $51 at Deutsche Bank
04/12/20
Airlines want Treasury to scrap proposal to make grant repayable, Reuters says
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
03/25/20 Deutsche Bank
Deutsche Bank upgrades eight Airlines to Buy on stimulus agreement
KMB Kimberly-Clark
$139.61 /

-0.21 (-0.15%)

03/30/20 Jefferies
Kimberly-Clark upgraded to Buy from Hold at Jefferies
02/25/20 Evercore ISI
Reynolds Consumer Products initiated with an Outperform at Evercore ISI
10/23/19 Deutsche Bank
Deutsche Bank upgrades Kimberly-Clark to Hold on expectations reset
10/22/19 Deutsche Bank
Kimberly-Clark upgraded to Hold from Sell at Deutsche Bank
DGX Quest Diagnostics
$94.57 /

-0.55 (-0.58%)

03/30/20 Wells Fargo
Quest Diagnostics price target lowered to $80 from $100 at Wells Fargo
03/27/20
Fly Intel: Top five analyst downgrades
03/27/20 Morgan Stanley
Morgan Stanley cuts Quest, upgrades Charles River in Healthcare Service shake-up
03/27/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
TER Teradyne
$60.88 /

-1.58 (-2.53%)

03/27/20 Deutsche Bank
Teradyne upgraded to Buy from Hold at Deutsche Bank
03/13/20 Northland
Northland upgrades Teradyne to Outperform as manufacturers diversify from China
03/13/20 Northland
Teradyne upgraded to Outperform from Market Perform at Northland
02/26/20 Citi
Teradyne price target lowered to $83 from $90 at Citi
CMG Chipotle
$781.00 /

-29.69 (-3.66%)

04/22/20 Cowen
Chipotle price target raised to $950 from $780 at Cowen
04/22/20 SunTrust
Chipotle price target raised to $946 from $841 at SunTrust
04/22/20 Wedbush
Chipotle price target raised to $870 from $860 at Wedbush
04/22/20 Baird
Chipotle price target raised to $950 from $920 at Baird
BIIB Biogen
$329.79 /

-9.33 (-2.75%)

03/31/20 Wolfe Research
Biogen initiated with a Peer Perform at Wolfe Research
03/26/20 Piper Sandler
Doctor survey shows 'massive' near-term COVID disruption, says Piper Sandler
03/13/20 Jefferies
Large-cap biotech remains good 'defensive zone' for 2020, says Jefferies
02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
NFLX Netflix
$434.01 /

-3.65 (-0.83%)

04/22/20 Cowen
Netflix price target raised to $485 from $445 at Cowen
04/22/20 Wedbush
Netflix price target raised to $198 from $194 at Wedbush
04/22/20 Deutsche Bank
Netflix price target raised to $500 from $400 at Deutsche Bank
04/22/20 Oppenheimer
Netflix price target raised to $480 from $400 at Oppenheimer
IBKR Interactive Brokers
$43.27 /

-1.09 (-2.46%)

04/06/20 Wells Fargo
Broker sector has plenty of fundamental challenges, says Wells Fargo
03/06/20 Wells Fargo
Wells Fargo cuts price targets for brokers on lower interest rate environment
10/03/19 Wells Fargo
Wells Fargo downgrades E-Brokers after material commission cuts
10/02/19
Fly Intel: Top five analyst upgrades
IRBT iRobot
$50.98 /

+0.41 (+0.81%)

04/22/20 JPMorgan
JPMorgan downgrades iRobot to Underweight on unfavorable risk/reward
04/22/20 JPMorgan
iRobot downgraded to Underweight from Neutral at JPMorgan
03/18/20 Piper Sandler
iRobot price target lowered to $41 from $51 at Piper Sandler
01/27/20 Piper Sandler
Piper 'incrementally more concerned' about iRobot due to price cuts
Hot Stocks
Immunic reports IMU-838 demonstrates activity against SARS-CoV-2 » 07:57
04/22/20
04/22
07:57
04/22/20
07:57
IMUX

Immunic

$7.83 /

-1.27 (-13.96%)

Last night, Immunic…

Last night, Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19. In cellular assays, IMU-838 demonstrated this antiviral activity at concentrations which are well below the blood concentrations associated with IMU-838 dosing regimens studied in ongoing and previous clinical trials. These results have encouraged Immunic to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics. IMU-838 is already being investigated in ongoing phase 2 clinical trials in patients with relapsing-remitting multiple sclerosis, ulcerative colitis and primary sclerosing cholangitis. Although the drug is being studied in these ongoing trials primarily for its anti-inflammatory effect, one of IMU-838's postulated benefits is a host-based antiviral effect, which may be important in these indications to potentially prevent virus reactivations known to occur with other immunomodulatory therapies. In support, IMU-838's antiviral activity has previously been demonstrated in vitro against human immunodeficiency virus, or HIV, hepatitis C virus, or HCV, human cytomegalovirus, or hCMV, Arenavirus and Influenza A virus. Given what is known about the natural course of the disease, IMU-838's combination of antiviral activity against the highly pathogenic SARS-CoV-2 and a selective immunomodulatory effect against highly activated immune cells may be a promising profile for the treatment of COVID-19. The company said IMU-838 has an attractive pharmacokinetic, safety and tolerability profile and, to date, has already been tested in about 650 individuals. Management noted that Immunic is collaborating with several regulatory agencies and other institutions in the United States and in Europe to define and accelerate the development path for IMU-838 in COVID-19. The aim is to investigate IMU-838 as an oral treatment option for COVID-19 and to enable the use of IMU-838 in treating current and potential future pandemic threats. Immunic intends to initiate a prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial in patients with moderate COVID-19 disease and clinical symptoms, in order to evaluate efficacy, safety and tolerability. The plan is to test IMU-838 versus placebo on the background of investigator's choice of standard-of-care therapy used in both treatment arms. Adequate drug supply exists to begin clinical testing in COVID-19 very soon.

ShowHide Related Items >><<
IMUX Immunic
$7.83 /

-1.27 (-13.96%)

03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
07/11/19
Fly Intel: Top five analyst initiations
07/11/19 Chardan
Immunic initiated with a Buy at Chardan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.